Business
I2Pure Celebrates Zimmer Biomet's Historic Approval of Iodine-Treated Implant System & Confirms AAHKS Attendance
ASHBURN, Va., October 06, 2025--I2Pure, a leader in molecular iodine technology, today celebrates Zimmer Biomet’s recent achievement in receiving Japan's Pharmaceutical and Medical Devices Agency (PMDA) approval for orthopedic implants utilizing iodine technology to inhibit bacterial adhesion on implant surfaces.
About this update from Zimmer Biomet Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/4581f63a348089a0978236b606ccb708"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8_.LP_7kLBXrU0GxPXunCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQxMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4581f63a348089a0978236b606ccb708","width":480,"height":206}},"lazy":false},{"type":"text","content":"Regulatory Approval Validates Molecular Iodine’s Remarkable Capabilities to Improve Healthcare & Patient Outcomes","length":117,"tagName":"p"},{"type":"text","content":"ASHBURN, Va., October 06, 2025--(BUSINESS WIRE)--I2Pure, a leader in molecular iodine technology, today celebrates Zimmer Biomet’s recent achievement in receiving Japan's Pharmaceutical and Medical Devices Agency (PMDA) approval for orthopedic implants utilizing iodine technology to inhibit bacterial adhesion on implant surfaces.","length":335,"tagName":"p"},{"type":"text","content":"This milestone represents further validation of molecular iodine's therapeutic potential in advanced medical applications. "We could not be more pleased to see Zimmer Biomet and the Japan PDMA recognize iodine as a biocompatible, essential body nutrient - a characterization that underscores the inherent biological compatibility and safety profile that makes molecular iodine an ideal candidate for infection prevention strategies," said Ilker Bayer, I2Pure’s Chief Scientist.","length":491,"tagName":"p"},{"type":"text","content":""The approval of iodine as an implant coating marks a watershed moment for molecular iodine applications in medical care," said Jeff Jochims, CEO at I2Pure. "This approval by a leading regulatory agency validates what we've long known: that molecular iodine offers unique advantages for infection management without contributing to antibiotic resistance. We’re excited to see a leading multinational manufacturer like Zimmer Biomet championing the inherent capabilities of molecular iodine for broader healthcare applications."","length":551,"tagName":"p"},{"type":"text","content":"The characterization of iodine as an "essential body nutrient" highlights a critical advantage in the fight against hospital-acquired an...